CD8A and cancer: Owing to these mechanistic features, numerous studies have examined the changes in the TME and circulatory immune cells, focusing on PD-1+CD8+ T cells before and after the administration of immune checkpoint inhibitors across various types of cancer [25,26,27,28,29].